Abstract
Pancreatic cancer will become the second leading cause of cancer-related death in the United States by 2030. Survival improves when it is identified at an early-stage and resected. Increasing public attention and cross-section imaging may shift detection to earlier stages. We found a small total increase in the proportion of stage-I cancer relative to all stages and a significant increase compared to distant disease in the Surveillance, Epidemiology, and End Results (SEER) database. Despite this, our ability to screen and identify early-stage disease is still lacking. Additional research and population-based interventions are necessary to improve early detection.
Disclosure statement
Sven P Oman: General payments/Minor Food and Beverage: Tenex Health Inc., Synergy Pharmaceuticals Inc.
Juan E Corral: Travel Grant: Abbvie, Inc. Minor Food and Beverage: Intercept Pharmaceuticals, Janssen Scientific, Boston Scientific Corporation and Cook Medical LLC.
John Stauffer: No conflicts of interest to disclose.
Massimo Raimondo: No conflicts of interest to disclose.
Kabir Mody: Consulting or Advisory Role: Celgene, Genentech, Eisai, AstraZeneca. Research Funding: Senhwa Biosciences, Merck Serono, MedImmune, AstraZeneca, Agios, Basilea, Taiho Pharmaceutical.
Michael B Wallace: Consulting: Virgo Inc, Cosmo/Aries Pharmaceuticals, Anx Robotica (2019), Covidien. Research grants: Fujifilm, Boston Scientific, Olympus, Medtronic, Ninepoint Medical, Cosmo/Aries Pharmaceuticals. Stock/Stock Options: Virgo Inc. Consulting on behalf of Mayo Clinic: GI Supply (2018), Endokey, Endostart, Boston Scientific. General payments/Minor Food and Beverage: Synergy Pharmaceuticals, Boston Scientific, Cook Medical.